Variate | 5-year survival rate (%) | |||||||
---|---|---|---|---|---|---|---|---|
OS | P | LRRFS | P | DMFS | P | DFS | P | |
Gender | Â | 0.173 | Â | 0.587 | Â | 0.077 | Â | 0.224 |
 Male | 75.8 |  | 87.1 |  | 75.3 |  | 65.9 |  |
 Female | 88.0 |  | 83.3 |  | 85.8 |  | 74.0 |  |
Age (years) | Â | 0.002 | Â | 0.489 | Â | 0.025 | Â | 0.007 |
 <50 | 82.8 |  | 87.0 |  | 81.5 |  | 73.1 |  |
 ≥50 | 68.6 |  | 84.6 |  | 68.4 |  | 55.6 |  |
WHO histology | Â | 0.362 | Â | 0.564 | Â | 0.526 | Â | 0.549 |
 Type II | 87.1 |  | 90.3 |  | 83.3 |  | 74.5 |  |
 Type III | 77.5 |  | 85.8 |  | 76.9 |  | 66.9 |  |
T stage | Â | 0.213 | Â | 0.070 | Â | 0.773 | Â | 0.299 |
 T1–2 | 84.4 |  | 96.4 |  | 81.3 |  | 78.1 |  |
 T3–4 | 77.4 |  | 84.6 |  | 76.9 |  | 66.0 |  |
N stage | Â | 0.934 | Â | 0.475 | Â | 0.414 | Â | 0.994 |
 N0–1 | 80.8 |  | 85.2 |  | 79.4 |  | 67.2 |  |
 N2–3 | 75.1 |  | 87.8 |  | 74.9 |  | 68.2 |  |
Overall stage | Â | <0.001 | Â | 0.518 | Â | 0.001 | Â | 0.004 |
 III | 85.6 |  | 87.7 |  | 84.9 |  | 74.7 |  |
 IV | 66.5 |  | 83.5 |  | 65.3 |  | 56.2 |  |
Treatment | Â | 0.599 | Â | 0.515 | Â | 0.456 | Â | 0.517 |
 NAC + IMRT | 78.0 |  | 87.9 |  | 79.0 |  | 69.8 |  |
 CCRT + AC | 78.7 |  | 84.8 |  | 76.2 |  | 65.6 |  |